drugset / Trial / NCT05518838

Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered

NCT05518838 ↗

Expanded access No longer available Oblato, Inc.

Summary

To provide OKN-007 for compassionate use in patients with diffuse midline glioma, H3 K27-altered (DMG), including diffuse intrinsic pontine glioma (DIPG), pediatric and young adult patients with high-grade diffuse midline glioma will be treated under this Intermediate-sized expanded access treatment protocol.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject DISUFENTON Small molecule — Intravenous